On July 3, CSPC Pharmaceutical rose 3.31% in regular trading, trading at HKD 7.95/share, with turnover of HKD 108 million. The stock continued to rally as markets digested a wave of positive developments announced the prior day.

On July 2, CSPC entered a strategic collaboration, option and license agreement with AstraZeneca covering its siRNA drug discovery and extrahepatic targeted delivery platforms for renal disease treatment. Under the deal, CSPC will receive USD 30 million upfront, up to USD 540 million in development milestones, up to USD 1.2 billion in sales milestones, and single-digit royalties. Additionally, CSPC's ADC drug SYS6043 was granted breakthrough therapy designation for platinum-resistant ovarian cancer, its iron sucrose injection obtained marketing approval, and its recombinant herpes zoster vaccine received clinical trial approval in China.

Within the Pharmaceuticals sector, the broader group strengthened in tandem. Among peers, Hansoh Pharma rose 4.79%, Hengrui Pharma rose 4.04%, and Luye Pharma rose 3.76%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)